Digital Therapeutics Complex Regional Pain Syndrome Global Market Report 2025

The digital therapeutics complex regional pain syndrome market size has grown rapidly in recent years. It will grow from $0.89 billion in 2024 to $1.05 billion in 2025 at a compound annual growth rate (CAGR) of 17.9%. The growth during the historic period is attributed to increasing recognition of the burden and undertreatment of chronic pain, opioid stewardship policies supporting nonpharmacological care, normalization of telehealth-delivered rehabilitation during the pandemic, payer pilots for digital pain programs and remote monitoring, and clinician adoption of guideline-supported biopsychosocial care.

The digital therapeutics complex regional pain syndrome market size is expected to see rapid growth in the next few years. It will grow to $2.01 billion in 2029 at a compound annual growth rate (CAGR) of 17.6%. The growth during the forecast period is attributed to the rising incidence of pain following orthopedic and trauma surgeries, increasing adoption of closed-loop and dorsal root ganglion (DRG) neuromodulation, favorable reimbursement updates for implantable spinal cord stimulation (SCS), autoimmune research driving intravenous immunoglobulin (IVIG) and monoclonal antibody (Mab) pipeline activity, and wearable biosensors enabling objective pain biomarkers. Key trends in the forecast period include artificial intelligence (AI)-driven pain assessment and personalization, wearable biosensors for continuous pain monitoring, virtual reality (VR) and augmented reality (AR)-based rehabilitation therapies, cloud-based platforms for real-time patient tracking, and digital twins for simulating pain response and optimizing treatment.

The expanding access to smartphones and internet connectivity is expected to drive the growth of the digital therapeutics for complex regional pain syndrome market in the coming years. Smartphones and internet connectivity enable users to communicate, access information, and utilize online services anytime and anywhere. The increasing availability of these technologies is driven by rapid urbanization, which creates infrastructure demands and economic conditions that accelerate the deployment of mobile networks and broadband services. Greater smartphone and internet penetration supports digital therapeutics by enabling continuous patient engagement, remote monitoring, and personalized therapy delivery through accessible mobile platforms, improving treatment adherence, real-time data collection, and overall pain management outcomes. For example, in May 2025, the US Federal Communications Commission reported that total connections rose by approximately 2.5% between June 2023 and June 2024, reaching 549 million. Mobile connections increased 2.5% year-over-year to 416 million, while fixed connections grew by about 2.3% to 133 million. This demonstrates that expanding access to smartphones and internet connectivity is driving market growth.

Rising healthcare expenditure is expected to propel the growth of the digital therapeutics for complex regional pain syndrome market. Healthcare expenditure includes the total financial resources allocated by governments, private insurers, businesses, and individuals toward medical services, treatments, medications, and related health activities. Increasing expenditure is driven by the growing prevalence of chronic diseases, which require long-term management and continuous therapeutic interventions. Higher healthcare spending supports demand for cost-effective solutions such as digital therapeutics, offering accessible and scalable pain management interventions without the recurring costs of traditional in-person care. For example, in June 2025, the US Centers for Medicare & Medicaid Services reported that national health expenditures increased by 7.5% in 2023, reaching $4.9 trillion, averaging $14,570 per person and representing 17.6% of GDP. Medicare spending rose by 8.1% to $1.02 trillion, accounting for 21% of total expenditures. This indicates that rising healthcare expenditure is driving market growth.

In November 2023, US-based BehaVR Inc. merged with Fern Health to form RealizedCare, a comprehensive digital care management platform for chronic pain and mental health. The merger aims to integrate digital therapeutics with traditional support services to deliver personalized, scalable, and value-based care for chronic pain and related mental health conditions. Fern Health Inc. specializes in providing virtual, evidence-based chronic pain management solutions, and the combined platform, RealizedCare, expands access to holistic digital care.

Major players in the digital therapeutics complex regional pain syndrome market are Abbott Laboratories, Hinge Health Inc., MedBridge Inc., Luna Innovations Inc., BioWave Inc., Kaia Health Software GmbH, XRHealth Inc., Vori Health Inc., AppliedVR Inc., Theranica Bio-Electronics Ltd., PainDrainer Inc., Physitrack Ltd., WellBrain Inc., Vitrue Health Inc., Upswing Health Inc., Flowly Inc., Plethy Inc., PainChek Ltd., Oska Wellness Inc., DarioHealth Corp.

North America was the largest region in the digital therapeutics complex regional pain syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in digital therapeutics for complex regional pain syndrome report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The digital therapeutics complex regional pain syndrome market research report is one of a series of new reports that provides digital therapeutics complex regional pain syndrome market statistics, including digital therapeutics complex regional pain syndrome industry global market size, regional shares, competitors with the digital therapeutics complex regional pain syndrome market share, digital therapeutics complex regional pain syndrome market segments, market trends, and opportunities, and any further data you may need to thrive in the digital therapeutics complex regional pain syndrome industry. This digital therapeutics complex regional pain syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Digital therapeutics for complex regional pain syndrome are evidence-based software treatments delivered via apps or online platforms that guide patients through validated therapies while monitoring symptoms and adherence. Their goal is to reduce pain and hypersensitivity, restore function and daily activities, and support clinicians with remote monitoring and personalized care, helping to reduce reliance on medications and frequent clinic visits.

The primary product types of digital therapeutics for complex regional pain syndrome include software, devices, and platforms. Software refers to programs and data that enable computers or devices to perform tasks, manage information, and interact effectively with users or other systems. These solutions are distributed through various channels, including online platforms, pharmacies, direct sales, and others. They are used for applications such as pain management, rehabilitation, and patient education, with key end users including hospitals, clinics, homecare settings, research institutes, and others.

The countries covered in the digital therapeutics for complex regional pain syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The digital therapeutics for complex regional pain syndrome market consists of revenues earned by entities by providing services such as prescription digital therapeutic program delivery, virtual reality pain rehabilitation sessions, remote patient monitoring and analytics, tele coaching and behavioral therapy support, and clinician decision-support and care-plan personalization. The market value includes the value of related goods sold by the service provider or included within the service offering. The digital therapeutics for complex regional pain syndrome market also includes sales of wearable sensors, monitoring devices, neurostimulation systems, and dorsal root ganglion stimulators. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.